

# Retinopathy Of Prematurity (Ophthalmology) - Drugs In Development, 2021

<https://marketpublishers.com/r/R37877A8BA5EEN.html>

Date: July 2021

Pages: 73

Price: US\$ 2,000.00 (Single User License)

ID: R37877A8BA5EEN

## Abstracts

Retinopathy Of Prematurity (Ophthalmology) - Drugs In Development, 2021

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinopathy Of Prematurity - Drugs In Development, 2021, provides an overview of the Retinopathy Of Prematurity (Ophthalmology) pipeline landscape.

Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies. This disorder which usually develops in both eyes is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness Risk factors for the development of ROP include prematurity, extremely low-birth-weight, and multiple births.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinopathy Of Prematurity - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinopathy Of Prematurity (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinopathy Of Prematurity and

features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Retinopathy Of Prematurity (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Retinopathy Of Prematurity (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Retinopathy Of Prematurity (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Retinopathy Of Prematurity (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Retinopathy Of Prematurity (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Retinopathy Of Prematurity - Overview
- Retinopathy Of Prematurity - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Retinopathy Of Prematurity - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Retinopathy Of Prematurity - Companies Involved in Therapeutics Development
- Advanced Imaging Projects Inc
- Anida Pharma Inc
- AntlerA Therapeutics Inc
- Ayuviv Research Inc
- D. Western Therapeutics Institute Inc
- Drive Therapeutics LLC
- Everglades Biopharma LLC
- Insmid Inc
- Kowa Co Ltd
- Novelty Nobility Inc
- Orphanix GmbH
- Pamdeca LLC
- Recordati Rare Diseases Inc
- Regeneron Pharmaceuticals Inc
- Signablock Inc
- Worphmed Srl
- Retinopathy Of Prematurity - Drug Profiles
- afibercept - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AVR-123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-2P014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Diabetic Retinopathy and Retinopathy of Prematurity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Retinopathy of Prematurity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mecasermin rinfabate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit SCG3 for Oncology, Ophthalmology and Diabetic Complications - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Agonize Frizzled receptor 4 and LRP5 for Diabetic Retinopathy and Retinopathy of Prematurity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuroprotectin D1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NN-2901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMD-336 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Propranolol hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ripasudil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Retinopathy of Prematurity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit TREM-1 for Oncology, Sepsis, Rheumatoid Arthritis,  
Retinopathy Of Prematurity and Hemorrhagic Shock - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Retinopathy Of Prematurity - Dormant Projects

Retinopathy Of Prematurity - Product Development Milestones

Featured News & Press Releases

Mar 11, 2019: Bascom Palmer's Dr. Wei Li awarded \$9.12 million NEI grant

Jun 30, 2016: Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in  
Extremely Premature Infants

Jan 21, 2009: Insmed And Premacure Announce European Orphan Designation For  
IPLEX In Retinopathy Of Prematurity In Infants

Appendix

Methodology

Coverage

Secondary Research

[Primary Research](#)  
[Expert Panel Validation](#)  
[Contact Us](#)  
[Disclaimer](#)



## List Of Tables

### LIST OF TABLES

Number of Products under Development for Retinopathy Of Prematurity, 2021  
Number of Products under Development by Companies, 2021  
Number of Products under Development by Universities/Institutes, 2021  
Products under Development by Companies, 2021  
Products under Development by Companies, 2021 (Contd..1)  
Products under Development by Universities/Institutes, 2021  
Number of Products by Stage and Target, 2021  
Number of Products by Stage and Mechanism of Action, 2021  
Number of Products by Stage and Route of Administration, 2021  
Number of Products by Stage and Molecule Type, 2021  
Retinopathy Of Prematurity - Pipeline by Advanced Imaging Projects Inc, 2021  
Retinopathy Of Prematurity - Pipeline by Anida Pharma Inc, 2021  
Retinopathy Of Prematurity - Pipeline by AntlerA Therapeutics Inc, 2021  
Retinopathy Of Prematurity - Pipeline by Ayuvis Research Inc, 2021  
Retinopathy Of Prematurity - Pipeline by D. Western Therapeutics Institute Inc, 2021  
Retinopathy Of Prematurity - Pipeline by Drive Therapeutics LLC, 2021  
Retinopathy Of Prematurity - Pipeline by Everglades Biopharma LLC, 2021  
Retinopathy Of Prematurity - Pipeline by Insmmed Inc, 2021  
Retinopathy Of Prematurity - Pipeline by Kowa Co Ltd, 2021  
Retinopathy Of Prematurity - Pipeline by Novelty Nobility Inc, 2021  
Retinopathy Of Prematurity - Pipeline by Orphanix GmbH, 2021  
Retinopathy Of Prematurity - Pipeline by Pamdeca LLC, 2021  
Retinopathy Of Prematurity - Pipeline by Recordati Rare Diseases Inc, 2021  
Retinopathy Of Prematurity - Pipeline by Regeneron Pharmaceuticals Inc, 2021  
Retinopathy Of Prematurity - Pipeline by Signablok Inc, 2021  
Retinopathy Of Prematurity - Pipeline by Worphmed Srl, 2021  
Retinopathy Of Prematurity - Dormant Projects, 2021

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Retinopathy Of Prematurity, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

## I would like to order

Product name: Retinopathy Of Prematurity (Ophthalmology) - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/R37877A8BA5EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R37877A8BA5EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970